{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:57:39Z","timestamp":1789001859067,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most studies on HPV vaccination have focused on the antibody response and on bivalent and quadrivalent vaccines. For these reasons, an evaluation of T-cell responses in PWH on effective ART to the Gardasil 9\u00ae vaccine according to prior HPV infection and baseline CD4 T-cell count was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively enrolled PWH on effective ART. T-cell responses were assessed by flow cytometry at pre-vaccination (T0), on the same day of the third dose (T1) and 6\u00a0months after the third dose (T2) after stimulation with a pool of HPV16 and HPV18 L1 peptide libraries. An evaluation of IFN-\u03b3 in supernatants was also carried out. Baseline CD4 T-cell count was defined at the first dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      An increase in the percentage of responding and polyfunctional T-cells was found in both HPV\u2009\u2212\u2009and HPV\u2009+\u2009groups, with no significant differences between them at any time point. When the population was stratified according to baseline CD4 T-cell count, an increase was found only in\u2009&gt;\u2009500 cells\/\u03bcL group for both the responding and polyfunctional T-cells. Furthermore, a higher frequency of responding CD4 T-cells at T1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0049), a higher frequency of responding CD8 T-cells at T1 and T2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.05 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02, respectively), a higher frequency of polyfunctional CD4 T-cells at T1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0242) and a higher frequency of polyfunctional CD8 T-cells at T2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) were found in\u2009&gt;\u2009500 cells\/\u03bcL group than in their relative counterpart.\n                    <\/jats:p>\n                    <jats:p>The analysis of the estimated change from T0 revealed no statistically significant differences between PWH with or without prior HPV infection, whereas significant associations between higher CD4 counts and improved immune responses were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study revealed a coordinated T-cell response against HPV16 and 18 after Gardasil9\u00ae vaccine in PWH, including those with a history of HPV infection. PWH with a lower CD4 T-cell count remains a group who may not mount a fully protective immune response and, therefore, may require additional protection or ad hoc vaccination strategies. These data reinforce the key role of basal CD4 level in modulating the immune response over time, while prior HPV infection did not significantly affect the rate and quality of the response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04504-1","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T09:59:52Z","timestamp":1766570392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of prior HPV infection and CD4 T-cell count in modulating cellular immune responses to a three-dose nonavalent HPV vaccine schedule in PWH receiving ART"],"prefix":"10.1186","volume":"23","author":[{"given":"Eeva","family":"Tortellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasilvia","family":"Guardiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ansaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Giovanna","family":"De Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Belvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonella","family":"Zingaropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Dominelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Falvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Mengoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tavelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Giambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Maria","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmo","family":"Del Borgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Marocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Lichtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"4504_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/14787210.2017.1392854","volume":"15","author":"M Poljak","year":"2017","unstructured":"Poljak M, \u0160terbenc A, Lunar MM. Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV). Expert Rev Anti-Infect Ther. 2017;15:987\u201399.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"4504_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/QAD.0000000000000922","volume":"30","author":"LS Park","year":"2016","unstructured":"Park LS, Hern\u00e1ndez-Ram\u00edrez RU, Silverberg MJ, et al. Prevalence of non-HIV cancer risk factors in persons living with HIV\/AIDS: a meta-analysis. AIDS Lond Engl. 2016;30:273\u201391.","journal-title":"AIDS Lond Engl"},{"key":"4504_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","volume":"13","author":"DA Machalek","year":"2012","unstructured":"Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13:487\u2013500.","journal-title":"Lancet Oncol"},{"key":"4504_CR4","unstructured":"CDC. CDC Works 24\/7. Centers for Disease Control and Prevention.\u00a02024. https:\/\/www.cdc.gov\/index.htm. Accessed 26 Mar 2024."},{"key":"4504_CR5","doi-asserted-by":"crossref","unstructured":"Geretti AM, BHIVA Immunization Writing Committee, Brook G, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med. 2008;9:795\u2013848.","DOI":"10.1111\/j.1468-1293.2008.00637.x"},{"key":"4504_CR6","doi-asserted-by":"publisher","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","volume":"26","author":"JT Schiller","year":"2008","unstructured":"Schiller JT, Castellsagu\u00e9 X, Villa LL, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26:K53\u201361.","journal-title":"Vaccine"},{"key":"4504_CR7","first-page":"100780","volume":"37","author":"S Aggarwal","year":"2023","unstructured":"Aggarwal S, Agarwal P, Singh AK. Human papilloma virus vaccines: a comprehensive narrative review. Cancer Treat Res Commun. 2023;37:100780.","journal-title":"Cancer Treat Res Commun"},{"key":"4504_CR8","unstructured":"Salute M della. Piano nazionale prevenzione vaccinale. https:\/\/www.salute.gov.it\/portale\/vaccinazioni\/dettaglioContenutiVaccinazioni.jsp?lingua=italiano&id=4828&area=vaccinazioni&menu=vuoto. Accessed 13 Jul 2023."},{"key":"4504_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrc.2018.13","volume":"18","author":"RBS Roden","year":"2018","unstructured":"Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18:240\u201354.","journal-title":"Nat Rev Cancer"},{"key":"4504_CR10","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","volume":"16","author":"JT Schiller","year":"2015","unstructured":"Schiller JT, M\u00fcller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 2015;16:e217\u201325.","journal-title":"Lancet Oncol"},{"key":"4504_CR11","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1016\/j.vaccine.2014.08.011","volume":"32","author":"V Giacomet","year":"2014","unstructured":"Giacomet V, Penagini F, Trabattoni D, et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine. 2014;32:5657\u201361.","journal-title":"Vaccine"},{"key":"4504_CR12","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1016\/j.vaccine.2013.09.032","volume":"31","author":"L Denny","year":"2013","unstructured":"Denny L, Hendricks B, Gordon C, et al. Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31:5745\u201353.","journal-title":"Vaccine"},{"key":"4504_CR13","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.vaccine.2019.03.034","volume":"37","author":"LA Pinto","year":"2019","unstructured":"Pinto LA, Wilkin TJ, Kemp TJ, et al. Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. Vaccine. 2019;37:2502\u201310.","journal-title":"Vaccine"},{"key":"4504_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1086\/656320","volume":"202","author":"T Wilkin","year":"2010","unstructured":"Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1\u2013infected men. J Infect Dis. 2010;202:1246\u201353.","journal-title":"J Infect Dis"},{"key":"4504_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/21645515.2017.1407896","volume":"14","author":"M Zurek Munk-Madsen","year":"2017","unstructured":"Zurek Munk-Madsen M, Toft L, Kube T, et al. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. Hum Vaccin Immunother. 2017;14:909\u201316.","journal-title":"Hum Vaccin Immunother"},{"key":"4504_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/cid\/ciab1052","volume":"75","author":"EPF Chow","year":"2022","unstructured":"Chow EPF, Fairley CK, Zou H, et al. Human papillomavirus antibody levels following vaccination or natural infection among young men who have sex with men. Clin Infect Dis. 2022;75:323\u20139.","journal-title":"Clin Infect Dis"},{"key":"4504_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/QAD.0000000000001773","volume":"32","author":"A Weinberg","year":"2018","unstructured":"Weinberg A, Huang S, Moscicki A-B, et al. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. AIDS. 2018;32:851\u201360.","journal-title":"AIDS"},{"key":"4504_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/cid\/ciu238","volume":"59","author":"EM Kojic","year":"2014","unstructured":"Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014;59:127\u201335.","journal-title":"Clin Infect Dis"},{"key":"4504_CR19","unstructured":"Benvenuta\/o a Latina Checkpoint. Latina Checkpoint.\u00a0https:\/\/www.latinacheckpoint.it\/. Accessed 31 Dec 2024."},{"key":"4504_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4161\/hv.19319","volume":"8","author":"D Jardine","year":"2012","unstructured":"Jardine D, Lu J, Pang J, et al. A randomized trial of immunotherapy for persistent genital warts. Hum Vaccines Immunother. 2012;8:623\u20139.","journal-title":"Hum Vaccines Immunother"},{"key":"4504_CR21","doi-asserted-by":"publisher","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","volume":"30","author":"JT Schiller","year":"2012","unstructured":"Schiller JT, Castellsagu\u00e9 X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30:F123\u201338.","journal-title":"Vaccine"},{"key":"4504_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/cid\/cir1036","volume":"54","author":"KA Swedish","year":"2012","unstructured":"Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54:891\u20138.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"4504_CR23","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.3390\/jcm12237317","volume":"12","author":"G Ciccarese","year":"2023","unstructured":"Ciccarese G, Herzum A, Serviddio G, et al. Efficacy of human papillomavirus vaccines for recalcitrant anogenital and oral warts. J Clin Med. 2023;12:7317.","journal-title":"J Clin Med"},{"key":"4504_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0264-410X(97)80918-8","volume":"16","author":"JE McElhaney","year":"1998","unstructured":"McElhaney JE, Gravenstein S, Upshaw CM, et al. Immune response to influenza vaccination in institutionalized elderly: effect on different T-cell subsets. Vaccine. 1998;16:403\u20139.","journal-title":"Vaccine"},{"key":"4504_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/376505","volume":"188","author":"LA Pinto","year":"2003","unstructured":"Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis. 2003;188:327\u201338.","journal-title":"J Infect Dis"},{"key":"4504_CR26","doi-asserted-by":"publisher","first-page":"7832","DOI":"10.1128\/JVI.76.15.7832-7842.2002","volume":"76","author":"RT Emeny","year":"2002","unstructured":"Emeny RT, Wheeler CM, Jansen KU, et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol. 2002;76:7832\u201342.","journal-title":"J Virol"},{"key":"4504_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","volume":"18","author":"C Lin","year":"2018","unstructured":"Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18:198\u2013206.","journal-title":"Lancet Infect Dis"},{"key":"4504_CR28","doi-asserted-by":"publisher","first-page":"149125","DOI":"10.1172\/JCI149125","volume":"131","author":"C Riou","year":"2021","unstructured":"Riou C, du Bruyn E, Stek C, et al. Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. J Clin Invest. 2021;131:149125.","journal-title":"J Clin Invest"},{"key":"4504_CR29","doi-asserted-by":"publisher","first-page":"14988","DOI":"10.3390\/ijms232314988","volume":"23","author":"E Tortellini","year":"2022","unstructured":"Tortellini E, Zingaropoli MA, Mancarella G, et al. Quality of T-cell response to SARS-CoV-2 mRNA vaccine in ART-treated PLWH. Int J Mol Sci. 2022;23:14988.","journal-title":"Int J Mol Sci"},{"key":"4504_CR30","doi-asserted-by":"publisher","first-page":"iqac005","DOI":"10.1093\/oxfimm\/iqac005","volume":"3","author":"C Mullender","year":"2022","unstructured":"Mullender C, da Costa KAS, Alrubayyi A, et al. SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxf Open Immunol. 2022;3:iqac005.","journal-title":"Oxf Open Immunol"},{"key":"4504_CR31","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1086\/433180","volume":"41","author":"ET Overton","year":"2005","unstructured":"Overton ET, Sungkanuparph S, Powderly WG, et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005;41:1045\u20138.","journal-title":"Clin Infect Dis"},{"key":"4504_CR32","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1038\/s41467-022-32263-7","volume":"13","author":"A Vergori","year":"2022","unstructured":"Vergori A, Cozzi Lepri A, Cicalini S, et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. Nat Commun. 2022;13:4922.","journal-title":"Nat Commun"},{"key":"4504_CR33","doi-asserted-by":"crossref","unstructured":"Woldemeskel BA, Karaba AH, Garliss CC, et al. The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021;74:1268\u201370.","DOI":"10.1093\/cid\/ciab648"},{"key":"4504_CR34","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1089\/aid.2011.0371","volume":"28","author":"C Agrati","year":"2012","unstructured":"Agrati C, Gioia C, Castilletti C, et al. Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients. AIDS Res Hum Retroviruses. 2012;28:1606\u201316.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4504_CR35","unstructured":"Antinori A, Cicalini S, Meschi S, et al. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clin Infect Dis. 2022;75:e552\u201363."},{"key":"4504_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00002030-199404000-00008","volume":"8","author":"FP Kroon","year":"1994","unstructured":"Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 1994;8:469\u201376.","journal-title":"AIDS"},{"key":"4504_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0167-5699(93)90320-K","volume":"14","author":"AA Freitas","year":"1993","unstructured":"Freitas AA, Rocha BB. Lymphocyte lifespans: homeostasis, selection and competition. Immunol Today. 1993;14:25\u20139.","journal-title":"Immunol Today"},{"key":"4504_CR38","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","volume":"24","author":"SL Giannini","year":"2006","unstructured":"Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937\u201349.","journal-title":"Vaccine"},{"key":"4504_CR39","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","volume":"25","author":"S-E Olsson","year":"2007","unstructured":"Olsson S-E, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931\u20139.","journal-title":"Vaccine"},{"key":"4504_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4161\/hv.18865","volume":"8","author":"CM Roteli-Martins","year":"2012","unstructured":"Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012;8:390\u20137.","journal-title":"Hum Vaccin Immunother"},{"key":"4504_CR41","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41590-023-01538-6","volume":"24","author":"M Buggert","year":"2023","unstructured":"Buggert M, Price DA, Mackay LK, et al. Human circulating and tissue-resident memory CD8+ T cells. Nat Immunol. 2023;24:1076\u201386.","journal-title":"Nat Immunol"},{"key":"4504_CR42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41385-021-00467-7","volume":"15","author":"J Lange","year":"2022","unstructured":"Lange J, Rivera-Ballesteros O, Buggert M. Human mucosal tissue-resident memory T cells in health and disease. Mucosal Immunol. 2022;15:389\u201397.","journal-title":"Mucosal Immunol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04504-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04504-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04504-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T09:59:53Z","timestamp":1766570393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04504-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4504"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04504-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Local Ethics Committee (protocol number 0879\/2024). Each subject gave written informed consent for participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"689"}}